Of particular interest are the findings that concomitant KRAS-activation and PTEN-loss induced progesterone-resistance and loss of stromal PR in endometrial tumors, but that progesterone sensitivity could be reintroduced through exogenous administration of PR into the stroma. The gene discussed is KRAS; the disease is endometrium neoplasm.